section name header

Interacting Drugs

OBJECT DRUGS

PRECIPITANT DRUGS

Proton Pump Inhibitors:


Comment:

In patients receiving antineoplastic doses of methotrexate, several proton pump inhibitors (PPIs) have been associated with methotrexate toxicity such as bone marrow suppression and GI toxicity. The risk with low-dose methotrexate (e.g., for arthritis) is probably much lower, but one should still be alert for evidence of methotrexate toxicity. Although there is limited information on potential interactions of pralatrexate with PPIs, one should assume that it may interact as well until clinical evidence is available.


Class 2: Use Only if Benefit Felt to Outweigh Risk